Related Experiment Videos

The influence of megadose methylprednisolone on experimental myocardial infarct size

Advances in Shock Research
|January 1, 1982
PubMed

Insights

Higher doses of methylprednisolone sodium succinate (MP) do not further reduce infarct size in myocardial infarction models. Early administration of MP at doses exceeding 30 mg/kg offers no additional cardioprotection.

Area of Science:

  • Cardiology
  • Pharmacology
  • Experimental Medicine

Background:

  • Previous studies showed methylprednisolone sodium succinate (MP) reduces infarct size.
  • The current study investigates if higher MP doses provide enhanced cardioprotection.

Purpose of the Study:

  • To determine the effect of increased methylprednisolone sodium succinate (MP) doses on myocardial infarct volume.
  • To compare the efficacy of MP "megadoses" against established therapeutic levels in a canine model of myocardial infarction.

Main Methods:

  • Mongrel dogs underwent LAD coronary artery ligation to induce myocardial infarction.
  • Animals received either a single 50 mg/kg MP dose (MP-50) or two 30 mg/kg MP doses (2MP-30).
  • Infarct volume was quantified using nitro-blue tetrazolium staining and weighing of unstained tissue.

Main Results:

  • Untreated control animals exhibited an average infarct size of 14.5% +/- 4.3%.
  • Both MP-50 and 2MP-30 treatments significantly reduced infarct size to 9.1%-9.6%.
  • No significant difference in infarct reduction was observed between "megadose" MP and previously established 30 mg/kg MP doses.

Conclusions:

  • Early administration of methylprednisolone sodium succinate (MP) at doses above 30 mg/kg does not provide additional protection against myocardial infarction.
  • Current therapeutic strategies using MP for acute myocardial infarction should adhere to established dosage guidelines.

Related Concept Videos